BOSTON, June 7, 2022
/PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA), the leading
horizontal platform for cell programming, today announced a
collaboration with Novo Nordisk, a leading global healthcare
company, to create novel expression hosts for pharmaceutical
products.
Today, hundreds of millions of people are living with diabetes,
obesity, and other serious chronic diseases, putting a strain on
individuals, families, and healthcare systems. More effective
medicines could improve treatment options for these people. Using
synthetic biology, Ginkgo and Novo Nordisk will collaborate to
unlock the potential of expression systems, which may accelerate
and enhance the discovery and development of Novo Nordisk's
biological medicines.
"Novo Nordisk is constantly pushing the boundaries for
innovative tools to bring new treatments to people living with
diabetes and other serious chronic diseases," said Brian Vandahl, Senior Vice President, Global
Research Technologies, Novo Nordisk. "Using synthetic biology and
the reprogramming of expression system genomes, we have the
potential to engineer biological systems that will expand the
chemical space of biological medicines."
"It's an honor to work with partners like Novo Nordisk that not
only have an incredible range of critically important products, but
that also provide us with the opportunity to do meaningful work
that could help so many patients," said Jason Kelly, CEO and cofounder of Ginkgo
Bioworks. "At Ginkgo, we are always on the lookout for projects
that will have an outsized impact on people's lives and well-being.
We're excited to be working with Novo Nordisk in our efforts to use
biology to create better medicines for patients with chronic
diseases."
Under the terms of the partnership, Ginkgo and Novo Nordisk will
launch a multi-year collaboration. Ginkgo will receive an upfront
R&D fee and is eligible to receive milestone payments as the
parties advance in the collaboration.
About Ginkgo Bioworks
Ginkgo is building a platform to
enable customers to program cells as easily as we can program
computers. The company's platform is enabling biotechnology
applications across diverse markets, from food and agriculture to
industrial chemicals to pharmaceuticals. Ginkgo has also actively
supported a number of COVID-19 response efforts, including K-12
pooled testing, vaccine manufacturing optimization and therapeutics
discovery. For more information, visit
www.ginkgobioworks.com.
Forward-Looking Statements of Ginkgo Bioworks
This
press release contains certain forward-looking statements within
the meaning of the federal securities laws, including statements
regarding the potential success of the collaboration and Ginkgo's
cell programming platform. These forward-looking statements
generally are identified by the words "believe," "can," "project,"
"potential," "expect," "anticipate," "estimate," "intend,"
"strategy," "future," "opportunity," "plan," "may," "should,"
"will," "would," "will be," "will continue," "will likely result,"
and similar expressions. Forward-looking statements are
predictions, projections and other statements about future events
that are based on current expectations and assumptions and, as a
result, are subject to risks and uncertainties. Many factors could
cause actual future events to differ materially from the
forward-looking statements in this press release, including but not
limited to: (i) the effect of Ginkgo's business combination with
Soaring Eagle Acquisition Corp. ("Soaring Eagle") on Ginkgo's
business relationships, performance, and business generally, (ii)
risks that the business combination disrupts current plans of
Ginkgo and potential difficulties in Ginkgo's employee retention,
(iii) the outcome of any legal proceedings that may be instituted
against Ginkgo related to its business combination with Soaring
Eagle, (iv) volatility in the price of Ginkgo's securities now that
it is a public company due to a variety of factors, including
changes in the competitive and highly regulated industries in which
Ginkgo operates and plans to operate, variations in performance
across competitors, changes in laws and regulations affecting
Ginkgo's business and changes in the combined capital structure,
(v) the ability to implement business plans, forecasts, and other
expectations after the completion of the business combination, and
identify and realize additional opportunities, (vi) the risk of
downturns in demand for products using synthetic biology, (vii) the
unpredictability of the duration of the COVID-19 pandemic and the
demand for COVID-19 testing and the commercial viability of our
COVID-19 testing business, and (viii) changes to the biosecurity
industry, including due to advancements in technology, emerging
competition and evolution in industry demands, standards and
regulations. The foregoing list of factors is not exhaustive. You
should carefully consider the foregoing factors and the other risks
and uncertainties described in the "Risk Factors" section of
Ginkgo's quarterly report on Form 10-Q filed with the U.S.
Securities and Exchange Commission (the "SEC") on May 16, 2022 and other documents filed by Ginkgo
from time to time with the SEC. These filings identify and address
other important risks and uncertainties that could cause actual
events and results to differ materially from those contained in the
forward-looking statements. Forward-looking statements speak only
as of the date they are made. Readers are cautioned not to put
undue reliance on forward-looking statements, and Ginkgo assumes no
obligation and does not intend to update or revise these
forward-looking statements, whether as a result of new information,
future events, or otherwise. Ginkgo does not give any assurance
that it will achieve its expectations.
GINKGO BIOWORKS INVESTOR
CONTACT:
investors@ginkgobioworks.com
GINKGO BIOWORKS MEDIA
CONTACT:
press@ginkgobioworks.com
View original content to download
multimedia:https://www.prnewswire.com/news-releases/ginkgo-bioworks-and-novo-nordisk-to-collaborate-on-expression-systems-for-pharmaceutical-products-301562508.html
SOURCE Ginkgo Bioworks